Bringing the Oncology Community Together

IP Chemo Improves Long-Term Survival in Ovarian Cancer

Published Online: Monday, July 15, 2013
Devansu Tewari, MD

Devansu Tewari, MD

Women with advanced ovarian cancer lived almost a year longer when treated with intraperitoneal (IP) chemotherapy instead of intravenous (IV) therapy, long-term follow-up from two randomized trials showed. The data were presented at the 2013 Annual Meeting of the Society of Gynecologic Oncology (SGO).

IP chemotherapy led to a median overall survival of 62 months compared with 51 months for IV therapy. IP treatment also slowed disease progression by 25% versus IV treatment, study author Devansu Tewari, MD, reported at the SGO meeting.

“Each of these trials demonstrated a significant advantage for intraperitoneal chemotherapy,” said Tewari, assistant professor of Obstetrics and Gynecology at the University of California, Irvine. “In this combined analysis, the survival advantage extends to a median follow-up past 10 years.”

The data also confirmed the importance of completing IP therapy, as the survival advantage increased with the number of cycles of therapy.

The results came from a combined analysis of the Gynecologic Oncology Group (GOG) 114 and 172 trials. GOG 114 compared IV cisplatin-paclitaxel versus a combination of IV carboplatin, IV paclitaxel, and IP cisplatin (J Clin Oncol. 2001;19:1001-1007). GOG 172 compared IV cisplatin-paclitaxel and a regimen consisting of IV paclitaxel followed by IP cisplatin-paclitaxel.

Both trials had progression-free survival (PFS) as their primary endpoint, and survival was a secondary endpoint. The trials involved a combined total of 876 women with stage III epithelial ovarian carcinoma, optimally resected to ≤1 cm residual tumor.

Tewari reported findings from a median follow-up of 13.8 years in GOG 114 and 9.7 years in GOG 172. The primary results of the individual trials showed a 5.5- to 6-month improvement in median PFS with IP therapy. In the combined analysis, the data continued to show a 5-month difference in favor of IP therapy (25 vs 20 months). After adjustment, the difference translated into a 16% reduction in the hazard ratio for progression (P = .03).

The initial reports of survival data showed an 11-month difference in favor of IP therapy in GOG 114 and a 16-month advantage for IP in GOG 172. In an adjusted analysis of the long-term follow-up data from both trials, patients receiving IP chemotherapy had a 17% lower mortality risk (P = .048).

Tolerance has been problematic with IP chemotherapy from the first clinical evaluations, an issue reflected in the data from GOG 114 and 172. The 5-year survival rate among patients treated with IP therapy increased from 18% with completion of one or two cycles to 33% with three or four cycles, to 59% for patients who completed five or six cycles of treatment. In GOG 172, only 42% of patients in the IP arm completed the planned six cycles of therapy.

Several ongoing studies are focusing on optimizing IP chemotherapy by evaluating different doses and different drug combinations.

In a discussion following Tewari’s presentation, Joan Walker, MD, noted that the consistency of the results from GOG 114, GOG 172, and the earlier GOG 104 trial have been encouraging, but “it can’t necessarily be [that] the IP therapy is the only contributing factor [to the survival improvement].”

“I don’t think this is going to be the end of the story,” said Walker, professor of Medicine at the University of Oklahoma in Oklahoma City.


Tewari D, Java J, Salani R, et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study (GOG#114/172, abstract). Presented at: 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 9-12, 2013; Los Angeles, CA. Abstract 6.


Related Articles
Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death
A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles
Ellen Matloff on Oophorectomy Timing for BRCA Carriers
Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.
Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families
Genetic counseling—including testing and risk assessment—is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.
Preventative Ovarian Surgery in BRCA1 Mutation Carriers More Beneficial Before Age 35
For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.